Prevention of transfusions

Problems in Anesthesia

Volumn 11, Issue 4, 1999, Pages 458-470

  Cahalan, Michael K ^a   Prough, Donald S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BLOOD AUTOTRANSFUSION; BLOOD TRANSFUSION REACTION; CASE REPORT; FEMALE; FLUID THERAPY; HEMOGLOBIN DETERMINATION; HUMAN; INFECTION RISK; MAJOR SURGERY; MALE; OXYGEN SATURATION; REVIEW; SCREENING TEST; TREATMENT INDICATION;

EID: 0033403507     PISSN: 08894698     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Wallace EL, Surgenor DM, Hao HS, An J, Chapman RH, Churchill WH. Collection and transfusion of blood and blood components in the United States, 1989. Transfusion 1993;33:139-144.
2. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts. Blood transfusion. N Engl J Med 1999;340:438-447.
3. AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997;127:904-909.
4. Consensus Conference. Perioperative red blood cell transfusion. JAMA 1988;260:2700-2703.
5. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84:732-747.
6. Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998;279:217-221.
7. Carson JL, Duff A, Berlin JA, et al. Perioperative blood transfusion and postoperative mortality. JAMA 1998; 279:199-205.
8. Thurer RL. Evaluating transfusion triggers. JAMA 1998;279:238-239.
9. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417.
10. Nelson AH, Fleisher LA, Rosenbaum SH. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med 1993;21:860-866.
11. Johnson RG, Thurer RL, Kruskall MS, et al. Comparison of two transfusion strategies after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg 1992;104:307-314.
12. Dietrich W, Barankay A, Dilthey G, Mitto HP, Richter JA. Reduction of blood utilization during myocardial revascularization. J Thorac Cardiovasc Surg 1989;97: 213-219.
13. Toy PT, Strauss RG, Stehling LC, et al. Predeposited autologous blood for elective surgery. A national multicenter study. N Engl J Med 1987;316:517-520.
14. Kanter MH, van Maanen D, Anders KH, Castro F, Mya WW, Clark K. Preoperative autologous blood donations before elective hysterectomy. JAMA 1996;276: 798-801.
15. Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995;332:719-724.
16. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts. Blood conservation. N Engl J Med 1999;340:525-533.
17. Schmoeckel M, Nollert G, Mempel M, Mempel W, Reichart B. Effects of recombinant human erythropoietin on autologous blood donation before open heart surgery. Thorac Cardiovasc Surg 1993;41:364-368.
18. Hayashi J, Kumon K, Takanashi S, et al. Subcutaneous administration of recombinant human erythropoietin before cardiac surgery: a double-blind, multicenter trial in Japan. Transfusion 1994;34:142-146.
19. Mercuriali F, Adamson JW. Recombinant human erythropoietin enhances blood donation for autologous use and reduces exposure to homologous blood during elective surgery. Semin Hematol 1993;30:17-21.
20. Milbrink J, Birgegard G, Danersund A, Helmers C, Nordstrom L, Sandhagen B. Preoperative autologous donation of 6 units of blood during rh-EPO treatment. Can J Anaesth 1997;44:1315-1318.
21. de Andrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC. Baseline hemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients. Am J Orthop 1996;25: 533-542.
22. Price TH, Goodnough LT, Vogler WR, et al. Improving the efficacy of preoperative autologous blood donation in patients with low hematocrit: a randomized, double-blind, controlled trial of recombinant human erythropoietin. Am J Med 1996;101:22S-27S.
23. Price TH, Goodnough LT, Vogler WR, et al. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion 1996;36:29-36.
24. Monk TG, Goodnough LT, Brecher ME, et al. Acute normovolemic hemodilution can replace preoperative autologous blood donation as a standard of care for autologous blood procurement in radical prostatectomy. Anesth Analg 1997;85:953-958.
25. Roberts SS. Blood safety in the age of AIDS. FASEB J 1996;10:391-402.
26. Napier JA, Bruce M, Chapman J, et al. Guidelines for autologous transfusion. II. Perioperative haemodilution and cell salvage. British Committee for Standards in Haematology Blood Transfusion Task Force. Autologous Transfusion Working Party. Br J Anaesth 1997; 78:768-771.
27. Goodnough LM, Grishaber JE, Birkmeyer JD, Monk TG, Catalona WJ. Efficacy and cost-effectiveness of autologous blood predeposit in patients undergoing radical prostatectomy procedures. Urology 1994;44: 226-231.
28. Toy PT, Menozzi D, Strauss RG, Stehling LC, Kruskall M, Ahn DK. Efficacy of preoperative donation of blood for autologous use in radical prostatectomy. Transfusion 1993;33:721-724.
29. Ness PM, Bourke DL, Walsh PC. A randomized trial of perioperative hemodilution versus transfusion of preoperatively deposited autologous blood in elective surgery. Transfusion 1992;32:226-230.
30. Petry AF, Jost J, Sievers H. Reduction of homologous blood requirements by blood-pooling at the onset of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;107:1210-1214.
31. Bryson GL, Laupacis A, Wells GA. Does acute normovolemic hemodilution reduce perioperative allogeneic transfusion? A meta-analysis. Anesth Analg 1998;86:9-15.
32. Desmond MJ, Thomas MJ, Gillon J, Fox MA. Consensus conference on autologous transfusion. Perioperative red cell salvage. Transfusion 1996;36:644-651.
33. Goodnough LT, Monk TG, Sicard G, et al. Intraoperative salvage in patients undergoing elective abdominal aortic aneurysm repair: an analysis of cost and benefit. J Vasc Surg 1996;24:213-218.
34. Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Paramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994;90: 921-927.
35. Baele PL, Ruiz-Gomez J, Londot C, Sauvage M, Van Dyck MJ, Robert A. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesthesiol Belg 1992;43: 103-112.
36. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993;55:971-976.
37. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990;73:1119-1126.
38. Dietrich W, Barankay A, Hahnel C, Richter JA. High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth 1992;6:324-327.
39. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107: 543-551.
40. Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994;107: 554-561.
41. Bailey CR, Kelleher AA, Wielogorski AK. Randomized placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery. Br J Surg 1994;81:969-973.
42. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-1291.
43. Cosgrove III DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54: 1031-1036.
44. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92: 2236-2244.
45. Menichetti A, Tritapepe L, Ruvolo G, et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg (Torino) 1996;37:401-407.
46. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997;85:1258-1267.
47. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting: a randomized, prospective, double-blind study. J Thorac Cardiovasc Surg 1994;108:99-108.
48. Katsaros D, Petricevic M, Snow NJ, Woodhall DD, Van Bergen R. Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients. Ann Thorac Surg 1996;61: 1131-1135.
49. Pugh SC, Wielogorski AK. A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 1995; 9:240-244.
50. Boldt J, Knothe C, Zickmann B, Wege N, Dapper F, Hempelmann G. Aprotinin in pediatric cardiac operations: platelet function, blood loss, and use of homologous blood. Ann Thorac Surg 1993;55:1460-1466.
51. Boldt J, Knothe C, Zickmann B, Wege N, Dapper F, Hempelmann G. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. J Thorac Cardiovasc Surg 1993;105:705-711.
52. Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 1993; 105:712-720.
53. Herynkopf F, Lucchese F, Pereira E, Kalil R, Prates P, Nesralla IA. Aprotinin in children undergoing correction of congenital heart defects. A double-blind pilot study. J Thorac Cardiovasc Surg 1994;108:517-521.
54. Grosse H, Lobbes W, Frambach M, von Broen O, Ringe B, Barthels M. The use of high dose aprotinin in liver transplantation: the influence on fibrinolysis and blood loss. Thromb Res 1991;63:287-297.
55. Mallett SV, Cox D, Burroughs AK, Rolles K. The intra-operative use of trasylol (aprotinin) in liver transplantation. Transpl Int 1991;4:227-230.
56. Patrassi GM, Viero M, Sartori MT, et al. Aprotinin efficacy on intraoperative bleeding and transfusion requirements in orthotopic liver transplantation. Transfusion 1994;34:507-511.
57. Smith O, Hazlehurst G, Brozovic B, et al. Impact of aprotinin on blood transfusion requirements in liver transplantation. Transfus Med 1993;3:97-102.
58. Janssens M, Joris J, David JL, Lemaire R, Lamy M. High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology 1994;80:23-29.
59. Surgenor DM, Wallace EL, Hao SH, Chapman RH. Collection and transfusion of blood in the United States, 1982-1988. N Engl J Med 1990;322:1646-1651.
60. Wallace EL, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995;35: 802-812.
61. Wallace EL, Churchill WH, Surgenor DM, Cho GS, McGurk S. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 1998;38:625-636.
62. Dodd RY. Adverse consequences of blood transfusion: quantitative risk estimates. In: Nance ST, ed. Blood Supply: Risks, Perceptions, and Prospects for the Future. Bethesda, MD: American Association of Blood Banks, 1994:1-24.
63. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-1690.
64. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721-1725.
65. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990;30:583-590.
66. Linden JV, Tourault MA, Scribner CL. Decrease in frequency of transfusion fatalities. Transfusion 1997; 37:243-244.
67. Ness PM, Shirey RS, Thoman SK, Buck SA. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion 1990;30:688-693.
68. Shulman IA. The risk of an overt hemolytic transfusion reaction following the use of an immediate spin cross-match. Arch Pathol Lab Med 1990;114:412-114.
69. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25:573-577.